SS-31 elamipretide · research summary

Innovative technologies for the treatment of dry age-related macular degeneration (AMD) - modern therapeutic perspectives and their future.

Romanian journal of ophthalmology · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Comprehensive review of current literature on therapeutic options for dry age-related macular degeneration.
“A comprehensive review of current literature was conducted, being focused on therapies for dry AMD, including classical methods such as AREDS/AREDS2 supplementation, molecularly targeted drugs, gene therapy, cell transplants, tissue engineering, nanotechnology, and light-based therapies.”

Subjects

Therapeutic approaches for dry age-related macular degeneration, including supplements, drugs, gene therapy, and technologies.
“This review explores modern therapeutic options for the dry form of age-related macular degeneration (AMD), a condition representing one of the most significant challenges in ophthalmology due to its progressive nature and lack of effective treatment.”

Duration

Literature from 2001 to 2024 was analyzed.
“Literature from 2001 to 2024 was analyzed using databases like PubMed and Scopus, focusing on molecular, nanotechnological, and genetic therapies.”

Reported findings

AREDS/AREDS2 therapies slow disease progression but cannot reverse retinal damage.
“AREDS/AREDS2 therapies effectively slow disease progression but cannot reverse retinal damage.”
Molecularly targeted therapies reduce inflammation and protect retinal cells.
“Advances include molecularly targeted therapies (Pegcetacoplan, Avacincaptad Pegol) that reduce inflammation, gene therapy (HMR59) protecting RPE cells, and mitochondria-targeted drugs (SS-31) mitigating oxidative stress.”
Emerging technologies like nanotechnology and AI aid in regeneration and prediction.
“Using scaffolds, nanoparticles, tissue engineering, and nanotechnology enhances RPE regeneration and drug delivery. Light-based therapies (LLLT, adaptive phototherapy) improve mitochondrial function, while AI aids in predicting disease progression and personalizing treatment.”

Limitations stated by the authors

Further clinical trials are needed to optimize strategies and assess long-term outcomes.
“However, further clinical trials are needed to optimize these strategies, assess long-term outcomes, and expand patient access to effective treatments.”

Source: PubMed 40330967 · DOI 10.22336/rjo.2025.03 · all study summaries

Study type

Comprehensive review of current literature on therapeutic options for dry age-related macular degeneration.

“A comprehensive review of current literature was conducted, being focused on therapies for dry AMD, including classical methods such as AREDS/AREDS2 supplementation, molecularly targeted drugs, gene therapy, cell transplants, tissue engineering, nanotechnology, and light-based therapies.”

Subjects

Therapeutic approaches for dry age-related macular degeneration, including supplements, drugs, gene therapy, and technologies.

“This review explores modern therapeutic options for the dry form of age-related macular degeneration (AMD), a condition representing one of the most significant challenges in ophthalmology due to its progressive nature and lack of effective treatment.”

Reported findings

AREDS/AREDS2 therapies slow disease progression but cannot reverse retinal damage.

“AREDS/AREDS2 therapies effectively slow disease progression but cannot reverse retinal damage.”

Molecularly targeted therapies reduce inflammation and protect retinal cells.

“Advances include molecularly targeted therapies (Pegcetacoplan, Avacincaptad Pegol) that reduce inflammation, gene therapy (HMR59) protecting RPE cells, and mitochondria-targeted drugs (SS-31) mitigating oxidative stress.”

Emerging technologies like nanotechnology and AI aid in regeneration and prediction.

“Using scaffolds, nanoparticles, tissue engineering, and nanotechnology enhances RPE regeneration and drug delivery. Light-based therapies (LLLT, adaptive phototherapy) improve mitochondrial function, while AI aids in predicting disease progression and personalizing treatment.”